At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SANA Sana Biotechnology, Inc.
Not Yet Opened 11-04 16:00:00 EST
3.76
+0.10
+2.73%
盘后3.80
+0.04+1.06%
18:51 EST
High3.81
Low3.53
Vol806.95K
Open3.66
D1 Closing3.66
Amplitude7.65%
Mkt Cap836.47M
Tradable Cap489.22M
Total Shares222.47M
T/O3.02M
T/O Rate0.62%
Tradable Shares130.11M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Integra Lifesciences (IART)
BRIEF-Sana Biotechnology Announces Increased Focus On Type 1 Diabetes And B-Cell Mediated Autoimmune Diseases With The Potential To Deliver Clinical Proof Of Concept Data Across Multiple Studies In 2024 And 2025
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-Cell Mediated Autoimmune Diseases With the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
BRIEF-Flagship Pioneering Announces Appointment Of Junaid Bajwa As Senior Partner, Head Of United Kingdom, And Science Partner For Pioneering Intelligence
Press Release: Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255, a B cell maturation antigen directed allogeneic CAR T for multiple myeloma; SC45, the PSC-derived pancreatic islet cells for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, Huntington's disease, and other astrocytic diseases. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is based in Seattle, Washington.